Sandbox:Sara: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(23 intermediate revisions by the same user not shown)
Line 2: Line 2:


{{CMG}}; {{AE}} {{S.M.}}
{{CMG}}; {{AE}} {{S.M.}}
*Treatment includes:<ref name="pmid31251395">{{cite journal| author=Huis In 't Veld EA, van Houdt WJ| title=Reply to Follow-up after treatment of dermatofibrosarcoma protuberans. | journal=Cancer | year= 2019 | volume= | issue= | pages= | pmid=31251395 | doi=10.1002/cncr.32341 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31251395 }} </ref><ref name="pmid16416612">{{cite journal| author=Loss L, Zeitouni NC| title=Management of scalp dermatofibrosarcoma protuberans. | journal=Dermatol Surg | year= 2005 | volume= 31 | issue= 11 Pt 1 | pages= 1428-33 | pmid=16416612 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16416612  }} </ref><ref name="pmid8646467">{{cite journal| author=Dawes KW, Hanke CW| title=Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. | journal=Dermatol Surg | year= 1996 | volume= 22 | issue= 6 | pages= 530-4 | pmid=8646467 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8646467  }} </ref><ref name="pmid10870053">{{cite journal| author=Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM et al.| title=Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. | journal=Cancer | year= 2000 | volume= 88 | issue= 12 | pages= 2711-20 | pmid=10870053 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10870053  }} </ref><ref name="pmid14983497">{{cite journal| author=DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK| title=Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. | journal=Cancer | year= 2004 | volume= 100 | issue= 5 | pages= 1008-16 | pmid=14983497 | doi=10.1002/cncr.20051 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14983497  }} </ref><ref name="pmid15221986">{{cite journal| author=Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB| title=Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. | journal=Cancer | year= 2004 | volume= 101 | issue= 1 | pages= 28-38 | pmid=15221986 | doi=10.1002/cncr.20316 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15221986  }} </ref>
 
** Imatinib-STI571 (tyrosine kinase inhibitor) therapy (may be effective in CD117- tumors) is the gold standard treatment of recurrent or inoperable tumor
 
** Excisional sugery including the removal of subcutaneous fat (i.e. wide local excision with 2 - 3 cm margins) alongwith 3-dimensional histologic evaluation of margins is necessarily recommended in order to prevent the tumor recurrence
 
*Treatment is primarily [[surgical]], with [[chemotherapy]] and [[radiation therapy]] sometimes being used. 
<ref name="pmid27261907">{{cite journal| author=Mao Y, Yang D, He J, Krasna MJ| title=Epidemiology of Lung Cancer. | journal=Surg Oncol Clin N Am | year= 2016 | volume= 25 | issue= 3 | pages= 439-45 | pmid=27261907 | doi=10.1016/j.soc.2016.02.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27261907 }} </ref>
*There is clinical evidence that [[imatinib]], which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation.
 
[[File:Atypical Bcell gif.gif|thumb|200px|none|High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-2&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=17 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.]]]
 
 
{|
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|}<br />
 
 
 
 
 
==Reference==
{{Reflist|2}}

Latest revision as of 18:18, 11 December 2020


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]


[1]

High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.


Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders
Criteria Symptomatic WM Asymptomatic WM IgM-Related Disorders MGUS
IgM monoclonal protein + + + +
Bone marrow infiltration + + - -
Symptoms attributable to IgM + - + -
Symptoms attributable to tumor infiltration + - - -




Reference

  1. ↑ Mao Y, Yang D, He J, Krasna MJ (2016). "Epidemiology of Lung Cancer". Surg Oncol Clin N Am. 25 (3): 439–45. doi:10.1016/j.soc.2016.02.001. PMID 27261907.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:Sara&oldid=1678042"